“…31 The present investigation supports the efficacy conclusion of previous ITI therapy studies. 22,23,32 rAHF was effective in a variety of ITI dosing regimens currently used in clinical practice. The estimated PPS and CAS cumulative success rates at 18 months were 72.4% and 68.3%, respectively, in patients who had both high-and low-titer inhibitors at baseline (information on whether inhibitors were low-or high-responding was not available).…”